Last reviewed · How we verify
NCT05210530
An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
Completed
Phase 1
Last updated 26 June 2023
What this trial tests
Phase 1 trial testing VCTX210A unit in Diabetes Mellitus in 7 participants. Completed in 19 January 2023.
Timeline
24 January 2022
Primary endpoint
19 January 2023
19 January 2023
19 January 2023
Quick facts
| Lead sponsor | CRISPR Therapeutics AG |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 7 |
| Start date | 24 January 2022 |
| Primary completion | 19 January 2023 |
| Estimated completion | 19 January 2023 |
| Sites | 3 locations across Canada |
Drugs / interventions tested
- VCTX210A unit
Conditions studied
- Diabetes Mellitus — all drugs for Diabetes Mellitus →
- Diabetes Mellitus, Type 1 — all drugs for Diabetes Mellitus, Type 1 →
- Glucose Metabolism Disorders — all drugs for Glucose Metabolism Disorders →
- Metabolic Disease — all drugs for Metabolic Disease →
Sponsor
CRISPR Therapeutics AG — full company profile →
Who can join
Adults 18 to 65, any sex, with Diabetes Mellitus or Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, multicenter, Phase 1 study evaluating the safety and tolerability of VCTX210A combination product in patients with T1D
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Encapsulated stem cell-derived β cells exert glucose control in patients with type 1 diabetes.
Keymeulen B, De Groot K, Jacobs-Tulleneers-Thevissen D, Thompson DM, et al · · 2024 · cited 72× · PMID 38012450 · DOI 10.1038/s41587-023-02055-5 -
Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine.
Khoshandam M, Soltaninejad H, Mousazadeh M, Hamidieh AA, et al · · 2024 · cited 62× · PMID 37588217 · DOI 10.1016/j.gendis.2023.02.027 -
Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
Sinclair F, Begum AA, Dai CC, Toth I, et al · · 2023 · cited 61× · PMID 36988873 · DOI 10.1007/s13346-023-01320-z -
CRISPR/Cas systems: Delivery and application in gene therapy.
Huang J, Zhou Y, Li J, Lu A, et al · · 2022 · cited 47× · PMID 36483767 · DOI 10.3389/fbioe.2022.942325 -
Current trends of clinical trials involving CRISPR/Cas systems.
Zhang S, Wang Y, Mao D, Wang Y, et al · · 2023 · cited 35× · PMID 38020120 · DOI 10.3389/fmed.2023.1292452 -
Emerging diabetes therapies: Bringing back the β-cells.
Basile G, Qadir MMF, Mauvais-Jarvis F, Vetere A, et al · · 2022 · cited 30× · PMID 35331962 · DOI 10.1016/j.molmet.2022.101477 -
Advancements in Human Embryonic Stem Cell Research: Clinical Applications and Ethical Issues.
Park SJ, Kim YY, Han JY, Kim SW, et al · · 2024 · cited 29× · PMID 38502279 · DOI 10.1007/s13770-024-00627-3 -
Advances in Nanoparticles as Non-Viral Vectors for Efficient Delivery of CRISPR/Cas9.
Kim M, Hwang Y, Lim S, Jang HK, et al · · 2024 · cited 27× · PMID 39339233 · DOI 10.3390/pharmaceutics16091197
Verify or expand the search:
- PubMed search for NCT05210530
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes Mellitus
Currently open trials in the same condition.
- NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
- NCT07392437 — Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and I · NA · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
- NCT07425275 — Integrated Oral Care Intervention for Xerostomia in Diabetes Patients · NA · recruiting
- NCT06918977 — Improving Glycemic Control With Telemedicine and Smart Insulin Pens · NA · recruiting
Other CRISPR Therapeutics AG trials
Trials by the same sponsor.
- NCT05795595 — A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors · Phase 1, PHASE2 · completed
- NCT04502446 — A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-L · Phase 1 · terminated
- NCT04438083 — A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) · Phase 1 · terminated
- NCT04244656 — A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma · Phase 1 · terminated
- NCT04035434 — A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) · Phase 1, PHASE2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05210530 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CRISPR Therapeutics AG
- Last refreshed: 26 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05210530.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing